Canada-based medical software company Tomoverse Imaging has raised $5m in its Seed funding round, led by a prominent Canadian Family Office.
Tomoverse intends to use the funding to accelerate the development of its AI-driven cardiac imaging platform and secure regulatory approvals from the US Food and Drug Administration (FDA), Health Canada, and other regulatory bodies.
The capital will also support the company’s strategic commercialisation efforts in North America and key global markets
Tomoverse Imaging CEO Stuart Kozlick said: “We are deeply grateful for the trust and confidence placed in us by our investors.
“This strategic investment accelerates our product roadmap, enabling us to bring our innovative technology closer to patients and clinicians who need it most.”
Based in Montreal, Canada, Tomoverse Imaging specialises in advancing cardiac CT imaging solutions for structural heart and coronary interventions.
Its flagship platform, tvCT, aims to modernise and streamline the planning and execution of complex transcatheter cardiac procedures, enhancing patient care and optimising outcomes.
Designed by physicians for physicians, the tvCT platform integrates advanced AI-based automated capabilities, significantly improving accuracy and efficiency in clinical workflows.
The platform enables fast analysis of cardiac CT images, providing real-time results to help clinicians plan structural heart interventions with confidence.
To ensure patient data security, the cloud-based platform complies with the highest security standards, using advanced encryption methods.
Tomoverse’s software is user-friendly and fully customisable, allowing clinicians to tailor it to their specific needs and preferences.
